Skip to content
DAEWOONG THERAPEUTICS

Commercial-scale delivery platform

Drug Delivery,
Designed.

Lab-Proven. GMP-Built. Commercial-Ready.

Explore platformsPartner with us

01 — Who we are

Better delivery turns good molecules into better medicines.

Daewoong Therapeutics specializes in innovative drug delivery system (DDS) technologies. A subsidiary of Daewoong Group, we develop our own clinical-stage DDS platforms and work openly with global pharmaceutical partners on patient-centric, DDS-based formulation and delivery solutions.

  • Trusted

    Proven platforms

    CLOPAM's high bioavailability is proven in humans, two of our programs have Phase 1 INDs approved, and Daewoong Group stands behind us.

  • Ready

    Commercial-ready

    An aseptic GMP patch plant already in operation, run with Daewoong Group's FDA cGMP experience in biologics.

  • Win-win

    Shared success

    Flexible models, from co-development to licensing, built so both sides grow with the product.

  • Easy start

    Low-barrier first step

    Begin with a feasibility study on your own molecule under an MTA, with no big commitment up front.

Part of Daewoong Group

The group's R&D, regulatory and GMP manufacturing strength stands behind every partnership.

About Daewoong Group

  • Research & development

    Fexuclue® and Envlo®, with more candidates in the clinic

  • Regulatory success

    Nabota® approved by the U.S. FDA

  • GMP manufacturing

    Global-standard plants in Hyangnam, with Seongnam to follow

Parent companyDaewoong Pharmaceutical (opens in a new tab)

02 — Platforms

Two platforms, built for partnership.

Each platform solves a different delivery problem. Bring your molecule — we'll help you find the right fit.

03 — Pipeline

Proven in our own programs, and with global partners.

  • In-houseDWRX 5001Peptide · microneedle patch · EndocrinologyPhase 1 IND approved · MFDS · Sep 2024CLOPAM
  • In-houseDWRX 5003Peptide · microneedle patch · ObesityPhase 1 IND approved · MFDS · Sep 2025CLOPAM
  • In-houseDWRX 5028Microneedle patch · weekly to monthly · Rare skin diseasePhase 1 IND submission · FDA · 1Q 2028CLOPAM
  • In-houseDWRX 5029Microneedle patch · weekly · Rare skin diseasePhase 1 IND submission · FDA · 2Q 2028CLOPAM
  • In-houseDWRX 6001ADC · subcutaneous formulationIND filing · Q2 – Q3 2028Thermicra
  • In-houseDWRX 6102mAb · ultra-high concentration biobetterPreclinicalThermicra
  • CollaborationPeptide · microneedle patchA top-tier global obesity & endocrinology companyIn progress · since 2025CLOPAM
  • CollaborationPeptide vaccine · microneedle patchAn R&D company in AsiaIn progress · since 2025CLOPAM
  • CollaborationTwo peptides · microneedle patchA top-tier global big pharmaIn progress · since 2026CLOPAM
  • CollaborationADC · subcutaneous formulationA top-tier global ADC developerIn progress · since 2025Thermicra
  • CollaborationADC · subcutaneous formulationAn R&D stage ADC developerIn progress · since 2026Thermicra
  • CollaborationmAb · subcutaneous formulationA top-tier global immunology companyIn progress · since 2026Thermicra
View pipeline

04 — Partnering

Ways to work with us

  1. 01Feasibility under an MTAValidate the platform on your own molecule under a material transfer agreement.
  2. 02Research collaborationBuild on the feasibility data and develop the formulation together.
  3. 03LicensingLicense the platform for your program.
  4. 04CommercializationTake the product to market with our continued technical support.

How it starts

  1. InquiryTell us about your molecule and goals.
  2. Quick meetingA short call on non-confidential information, to see whether there is a fit.
  3. CDAWe sign a confidentiality agreement before exchanging details.
  4. FeasibilityUnder an MTA, we evaluate your molecule and share the data.
  5. AgreementWe agree the collaboration model and terms.
How we partner

Let's talk about your molecule.

Tell us what you are developing. We'll come back with how CLOPAM or Thermicra could help.
Start a conversation